Riskpilot← Back to searchSign inGet full accessGG Internmedicin AB
ABActiveOrg 5591878284Sätuna VekabergMedical specialists activities · NACE 8622Est. 20181 employees
Revenue 2024
SEK 6,8M
+71% vs 2023
EBITDA margin
43.3%
+3% vs 2023
Equity ratio
77.9%
Financial strength
Net profit 2024
SEK 2,4M
+10% vs 2023
| Revenue | SEK 6,8M | +71% |
| EBITDA | SEK 2,9M | +3% |
| Net profit | SEK 2,4M | +10% |
| Total assets | SEK 11,6M | +31% |
| Equity | SEK 9,1M | +27% |
| Employees | 1 | — |
Legal name
GG Internmedicin AB
Org number
5591878284
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
20 december 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att verka som läkare med konsultverksamhet inom allmänmedicin, internmedicin och medicinska mag-, tarm- och leversjukdomar samt därmed förenlig verksamhet.
Address
Sätuna Vekaberg
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 138 | 2 694 | 3 197 | 3 951 | 6 754 |
| Staff expenses | — | — | −741 | −705 | −967 |
| EBITDA | 1 910 | 2 358 | 2 250 | 2 831 | 2 926 |
| Depreciation & amort. | −0 | −0 | −56 | −154 | −154 |
| EBIT | 1 910 | 2 358 | 2 195 | 2 677 | 2 772 |
| Net financials | — | −2 | −5 | 101 | 270 |
| Profit before tax | 1 910 | 2 356 | 2 190 | 2 778 | 3 042 |
| Tax | −409 | −492 | −453 | −581 | −633 |
| Net profit | 1 501 | 1 864 | 1 737 | 2 197 | 2 409 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 181 | 5 146 | 7 104 | 8 851 | 11 636 |
| Equity | 2 120 | 3 804 | 5 353 | 7 112 | 9 062 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 062 | 1 342 | 1 751 | 1 739 | 2 574 |
| Total debt | 1 062 | 1 342 | 1 751 | 1 739 | 2 574 |
EBITDA margin
43.3%
This company
15.8%
Market median
+174% vs market
20202024
Equity ratio
77.9%
This company
38.2%
Market median
+104% vs market
20202024
Return on equity
26.6%
This company
18.4%
Market median
+45% vs market
20202024
Net profit margin
35.7%
This company
8.1%
Market median
+341% vs market
20202024
Asset turnover
0.58×
This company
1.12×
Market median
-48% vs market
20202024
Debt / equity
0.28×
This company
0.62×
Market median
+55% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MD Chief Auditor | Chief Auditor | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GG Internmedicin AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mikaela Dorothea Vidåkra | Chief Auditor | 0 companies |
| Kent Evert Dighammar | Deputy Board Member | 0 companies |
| Nils Gösta Göthlund | Board of Directors | 0 companies |